High risk elderly AF patients benefit from good quality anticoagulation control
21-10-2015 • Senoo K and Lip GYH, Stroke 2015
Elderly patients are at high risk of CV death and stroke/systemic embolism, but age does not increase risk of any clinically relevant bleeding. High TTR negatively correlated with adverse outcomes.
News • 19-10-2015
German AFNET and EHRA lay out roadmap to improve AF management
Many people have undiagnosed and therefore untreated AF, associated with high risk of strokes and death. AFNET and EHRA composed recommendations aimed to improve AF diagnosis and treatment.
Risk prediction with SCORE model not improved by addition HDL-C
6-10-2015 • Mortensen MB et al., Eur Heart J 2015
The newly recommended SCORE-HDL model did not improve discrimination between cases and non-cases in a ‘low-risk’ country, and both models overestimate risk of fatal CVD in this population.
News • 28-9-2015
Next step on the way to approval of first antidote to anticoagulant effect of NOAC
Following accelerated assessment, EMAs CHMP recommends granting a marketing authorisation for idarucizumab, a reversal agent for dabigatran, given its potential to respond to an unmet medical need.
Glucose-lowering agent shows CV benefit in outcome trial, for the first time
21-9-2015 • Zinman B et al., NEJM 2015
Treatment with SGLT2 inhibitor empagliflozin in addition to standard care reduces CV mortality, nonfatal MI and stroke in T2DM patients at high CV risk, shows the EMPA-REG OUTCOME trial.
News • 7-9-2015
Using two common diuretics at half dose is effective without undesired side effects
The combination of amiloride and hydrochlorothiazide, each at half dose, can significantly reduce BP without the side-effects caused by full doses of either alone, the PATHWAY 3 study showed.
News • 20-10-2015
EPCCS consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care
General practitioners representing various European countries discussed recent developments in the SPAF field, and specific implications for primary care in an expert meeting. This meeting resulted in a practical guidance for European GPs.
In CVD-free individuals, risk of diabetes increases with elevated blood pressure
7-10-2015 • Emdin CA et al., J Am Coll Cardiol. 2015
Risk of new onset diabetes increased with higher SBP and DBP. Relative risk increase was lower in older people and those with BMI>35, but absolute risk remained substantial in those individuals.
News • 29-9-2015 • Prague, Sept 17-18, 2015
Lively debate at annual EPCCS Clinical Masterclass to yield practical guidance
This year’s EPCCS Meeting dedicated much time to discussion and identifying gaps in the evidence, aimed at composing practical recommendations for CV risk management in general practice.
The role of nonstatin lipid-modifying agents in CV risk management
28-9-2015 • Hegele RA et al., ATVB 2015
Recent data show that similar CV benefits can be achieved with nonstatin agents, as with statins, suggesting that pleiotropic effects of statins are not central to their effects.
News • 7-9-2015
New heart failure agent also beneficial at systolic hypertension and arterial stiffness
LCZ696 lowers central blood pressure and pulse pressure more effectively than an angiotensin receptor blocker in a high-risk population with systolic hypertension and increased pulse pressure.
News • 5-9-2015
Spironolactone most effective treatment for resistant hypertension
In patients with resistant hypertension, addition of the diuretic spironolactone was significantly more effective than adding other BP-lowering drugs, according to results of the PATHWAY-2 trial.
20th WONCA Europe Conference
22 - 25 oktober 2015, Istanbul, Turkey
All upcoming meetings...
Meeting reports & resources
Report of 8th Annual EPCCS meeting held in Prague.
Report of 7th Annual EPCCS meeting held in Brussels.
Report of 6th Annual EPCCS meeting held in London
Report of 5th Annual EPCCS meeting held in Athens
All meeting reports...